EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Toward a ready-to-use blood collection tube preventing direct oral anticoagulant-interference with routine coagulation assays

Mohamed Ghalloussi, Kimberley Chemmama, Maïlys Le Guyader, Virginie Siguret, Pauline Hubert, Annelise Voyer, Momar Diouf, Antoine Galmiche, Thomas Boyer, Loïc Garçon, Georges Jourdi, Julien Demagny

Journal of Thrombosis and Haemostasis · 2026-07 · 24 (7) · 2449-2460

DOI: 10.1016/j.jtha.2026.03.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-07. Verfasst von Mohamed Ghalloussi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hématologie Biologique, CHU Amiens-Picardie, Amiens, France. Hauptthemen laut MEDLINE: Blood Coagulation, Blood Specimen Collection, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Direct oral anticoagulants (DOACs) interfere with many coagulation assays. While in vitro plasma treatment with activated charcoal can overcome such interference, it requires technical support and is unsuitable for high-throughput workflows. OBJECTIVES: To circumvent such limitations, we added activated charcoal directly to citrated blood collection tubes and assessed the impact of such an approach on coagulation assays. METHODS: DOAC-spiked and patient whole blood samples (with and without DOACs) were treated with activated charcoal. Outcomes were residual DOAC plasma levels, routine coagulation assays, and specialized hemostasis assays (antithrombin, protein C, protein S, lupus anticoagulant testing, and thrombin generation assay). RESULTS: DOACs became undetectable in 118 of 122 samples from patients who received DOAC after 10 minutes of treatment with activated charcoal. DOAC interference with prothrombin time and activated partial thromboplastin time was resolved in almost all samples from patients who received DOAC; fibrinogen, factor V, and D-dimer levels remained unchanged. Whole blood contact with activated charcoal led to a slight prolongation in prothrombin time and activated partial thromboplastin time and a small decrease in fibrinogen level in blood samples from patients without anticoagulated therapies, yet these changes were not clinically relevant. Conversely, the level of endogenous coagulation inhibitors was significantly reduced, and the level of thrombin generation was significantly enhanced. CONCLUSION: Adding activated charcoal to whole blood corrected DOAC interference with routine coagulation assays with minimal, if any, impact on the results in the absence of DOACs, thus supporting the development of citrated blood collection tubes preloaded with activated charcoal. Their use would accelerate the laboratory workflow and lead to reliable routine hemostasis assay results in all patients receiving DOACs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood CoagulationBlood Specimen CollectionAnticoagulantsHumansBlood Coagulation TestsCharcoalAdministration, OralPartial Thromboplastin TimeProthrombin TimePredictive Value of Tests

Stichwörter der Autor:innen

blood coagulation testscharcoaldabigatranfactor Xa inhibitors

Substanzen

CharcoalAnticoagulants

Autor:innen und Institutionen

  • Service d'Hématologie Biologique, CHU Amiens-Picardie, Amiens, France.
  • Service d'Hématologie Biologique, Hôpital Lariboisière, Assistance Publique des Hôpitaux de Paris Nord (APHP.Nord), Paris, France; Université Paris Cité, INSERM, UMRS-1144, Optimisation Thérapeutique en Neuropharmacolog…
  • Université Paris Cité, INSERM, UMRS-1144, Optimisation Thérapeutique en Neuropharmacologie, Paris, France.
  • Département de biostatistiques, Direction de la Recherche Clinique et de l'Innovation, CHU Amiens-Picardie, Amiens, France.
  • Laboratoire de Biochimie, CHU Amiens-Picardie, Amiens, France.
  • Service d'Hématologie Biologique, CHU Amiens-Picardie, Amiens, France; HEMATIM UR666, Jules Verne University of Picardie, Amiens, France.

Zitieren

APA

Ghalloussi, M., Chemmama, K., Le Guyader, M., Siguret, V., Hubert, P., Voyer, A., Diouf, M., Galmiche, A., Boyer, T., Garçon, L., Jourdi, G., & Demagny, J. (2026). Toward a ready-to-use blood collection tube preventing direct oral anticoagulant-interference with routine coagulation assays. Journal of Thrombosis and Haemostasis, 24(7), 2449-2460. https://doi.org/10.1016/j.jtha.2026.03.015

Vancouver

Ghalloussi M, Chemmama K, Le Guyader M, Siguret V, Hubert P, Voyer A, et al. Toward a ready-to-use blood collection tube preventing direct oral anticoagulant-interference with routine coagulation assays. Journal of Thrombosis and Haemostasis. 2026;24(7):2449-2460. doi:10.1016/j.jtha.2026.03.015

BibTeX
@article{Ghalloussi2026,
  author = {Ghalloussi, Mohamed and Chemmama, Kimberley and Le Guyader, Maïlys and Siguret, Virginie and Hubert, Pauline and Voyer, Annelise and Diouf, Momar and Galmiche, Antoine and Boyer, Thomas and Garçon, Loïc and Jourdi, Georges and Demagny, Julien},
  title = {Toward a ready-to-use blood collection tube preventing direct oral anticoagulant-interference with routine coagulation assays},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {7},
  pages = {2449--2460},
  doi = {10.1016/j.jtha.2026.03.015}
}
Kostenlos starten →